StockReport.com is a 7:00 PM newsletter with a pertinent stock report every day, plus the lates market news.
Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.
The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery. Beyond Korlym, Corcept is advancing a proprietary pipeline of selective glucocorticoid receptor modulators, most notably relacorilant. Relacorilant is under investigation in multiple clinical trials for indications including endogenous Cushing’s syndrome, platinum-resistant ovarian cancer and psychotic major depression, reflecting Corcept’s commitment to expanding therapeutic options where cortisol dysregulation plays a key role.
Founded in 1998 and headquartered in Redwood City, California, Corcept went public in 2012 to support its transition from research to commercialization. Since then, the company has built a specialized commercial organization in the United States and is pursuing regulatory filings and partnerships in Europe and other regions. Corcept collaborates with academic institutions, clinical research centers and regulatory authorities to advance its programs from proof of concept through pivotal trials.
Corcept is led by President and CEO Joseph K. Belanoff, M.D., who co-founded the company and has guided its scientific and strategic direction for more than two decades. Under his leadership, Corcept has established a multidisciplinary team of researchers, clinicians and commercial experts. The company continues to explore novel approaches to glucocorticoid receptor modulation with the goal of delivering transformative therapies for patients affected by debilitating cortisol-related disorders.
Tiny Lebanon sits on one of the largest gold reserves in the Middle East and its government is weighing whether to use that stockpile to restore a crippled economy while its citizens are looking at gold as a way to revive their battered finances
Amazon sales surged 14% during the fourth quarter, helped by strong holiday spending and a better-than-expected growth in its prominent cloud computing unit.But shares fell 11% in after hours trading on Thursday as investors appeared to be spooked by the Seattle-based tech company's plans to increas...
Sharp drops hit Wall Street on Thursday as technology stocks fell and bitcoin plunged again to roughly half its record price set last fall. Several discouraging reports on the U.S. job market also knocked down yields in the bond market.The S&P 500 fell 1.2% for its sixth loss in the seven days ...
PayPal is replacing CEO Alex Chriss with Enrique Lores, saying that the pace of change and execution at the company has not met board expectations over the past two years.Lores has served as a PayPal board member for almost five years and has been board Chair since July 2024. He's also spent more th...